Chiron Corporation

Cetus Corporation

Novartis Vaccines & Diagnostics, Gmbh

Xoma Technology Ltd.

Cetus Oncology Corporation

Other

Kirston E Koths

Robert F Halenbeck

George A Martin

Ernest S Kawasaki

Martha B Ladner

Mazie Yee Coyne

Eric W Taylor

Janelle A Noble

Alice M Wang

Arnold H Horwitz

Cheng Liu

Michael Kriegler

Carl F Perez

Walter J Laird

Li Long

David A Jewell

Maria Calderon-Cacia

William Michael Kavanaugh

Deborah Lee Zimmerman

Gregory Martin Harrowe

Clayton L Casipit

Kenneth L Wilson

Cynthia A Cowgill

Michael G Kunitani

James W Thomson

Janelle N Van Arsdell

Wolf Hanisch

Margaret Moreland

Francis P McCormick

Sung-Hou Kim

L L Houston

Nandini Katre

Anna Lisa Fear

Jarmila Jancarik

Jayvardhan Pandit

Ralph Yamamoto

Andrew Bohm

Paul Stevens

Brian Issell

Paula J Shadle

Mary M Trahey

David B Ring

Danute E Nitecki

Michael A Innis

Lois Aldwin

W Michael Kavanaugh

Bonnee Rubinfeld

David F Mark

Ze'ev Shaked

Robert Zimmerman

Gail L Wong

Robin Clark

Peter M Fernandes

Edward C O'Rourke

Jan Tuttleman

John D Young

Danutee Nitecti

Frank P McCormick

Joseph W Wrin

M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof

M-CSF specific monoclonal antibody and uses thereof

M-CSF specific monoclonal antibody and uses therof

Methods and materials are disclosed for the production of purified, active recombinant human neutrophil protease, PR-3, via activation of a pro-form herein referred to as proPR-3. Human PR-3 is useful for discovering inhibitors of excessive release of mature, active TNF&agr;. Also disclosed are methods for the identification of inhibitors of the conversion of the pro-form of TNF&agr; to its mature active form.

Recombinant PR-3 and assays employing the same

Recombinant PR-3 and compositions thereof

The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free, the dimeric CSF-1 consisting essentially of two monomeric human CSF-1 subunits. The present invention is further directed to pharmaceutical compositions comprising the same.

Recombinant human CSF-1 dimer and compositions thereof

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both &ldquo;long&rdquo; and &ldquo;short&rdquo; forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

DNA encoding N&nabla;2 CSF-1 (short form) and carboxy truncated fragment thereof

The present invention is directed to methods for crystallizing macrophage colony stimulating factor. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.

Soluble extracellular domain of human M-CSF receptor

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both 'long' and 'short' forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both 'long' and 'short' forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

DNA encoding NV2 (long form) and carboxy truncated fragments thereof

N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof

N.gradient.2 CSF-1 (short form) and carboxy truncated fragments thereof

A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approtely 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.

Secreted mac-2-binding glycoprotein

Identification of M-CSF agonists and antagonists

Growing community of inventors

El Cerrito, CA, United States of America

Kirston E Koths